BNP Paribas set a GBX 1,620 ($20.92) target price on GlaxoSmithKline plc (LON:GSK) in a research note released on Wednesday morning. The firm currently has a neutral rating on the stock.

Several other research analysts have also commented on the stock. Goldman Sachs Group, Inc. (The) set a GBX 1,900 ($24.54) price objective on shares of GlaxoSmithKline plc and gave the stock a buy rating in a research note on Wednesday, July 26th. Barclays PLC reiterated an equal weight rating and set a GBX 1,550 ($20.02) price objective on shares of GlaxoSmithKline plc in a research note on Monday, July 3rd. Jefferies Group LLC reiterated a buy rating and set a GBX 1,900 ($24.54) price objective on shares of GlaxoSmithKline plc in a research note on Thursday, July 13th. Berenberg Bank upgraded shares of GlaxoSmithKline plc from a hold rating to a buy rating and boosted their price objective for the stock from GBX 1,850 ($23.89) to GBX 1,885 ($24.34) in a research note on Friday, May 26th. Finally, Deutsche Bank AG reiterated a hold rating and set a GBX 1,720 ($22.21) price objective on shares of GlaxoSmithKline plc in a research note on Tuesday, July 25th. Four equities research analysts have rated the stock with a sell rating, ten have given a hold rating and eight have issued a buy rating to the company’s stock. The stock currently has an average rating of Hold and an average price target of GBX 1,714.48 ($22.14).

Shares of GlaxoSmithKline plc (LON:GSK) opened at 1494.00 on Wednesday. GlaxoSmithKline plc has a 12-month low of GBX 1,446.50 and a 12-month high of GBX 1,745.56. The stock’s 50 day moving average is GBX 1,521.96 and its 200-day moving average is GBX 1,615.99. The stock’s market cap is GBX 73.03 billion.

TRADEMARK VIOLATION WARNING: This piece was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark legislation. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/09/bnp-paribas-analysts-give-glaxosmithkline-plc-gsk-a-gbx-1620-price-target.html.

The company also recently declared a dividend, which will be paid on Thursday, October 12th. Investors of record on Thursday, August 10th will be issued a dividend of GBX 19 ($0.25) per share. This represents a yield of 1.23%. The ex-dividend date is Thursday, August 10th.

In other news, insider Manvinder Singh Banga purchased 2,267 shares of the stock in a transaction that occurred on Wednesday, July 26th. The shares were purchased at an average cost of GBX 1,599 ($20.65) per share, with a total value of £36,249.33 ($46,815.61). Also, insider Patrick Vallance purchased 861 shares of the stock in a transaction that occurred on Friday, July 14th. The shares were purchased at an average cost of GBX 1,618 ($20.90) per share, for a total transaction of £13,930.98 ($17,991.71). Insiders have purchased 3,144 shares of company stock worth $5,043,015 over the last three months.

About GlaxoSmithKline plc

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Receive News & Stock Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related stocks with our FREE daily email newsletter.